The (Re)-emerging And ePidemic Infectious Diseases (RAPID) Stigma Scales: a cross-outbreak scale development and pyschometric validation study
- PMID: 40456231
- DOI: 10.1016/S1473-3099(25)00161-6
The (Re)-emerging And ePidemic Infectious Diseases (RAPID) Stigma Scales: a cross-outbreak scale development and pyschometric validation study
Abstract
Reducing stigma during infectious disease outbreaks is crucial for delivering an effective response. However, no validated stigma scales exist for use across outbreaks, and outbreak-specific scales are developed too slowly to guide timely interventions. To enable more real-time monitoring and mitigation of stigma across outbreak contexts, we developed and validated the (Re)-emerging and ePidemic Infectious Diseases (RAPID) Stigma Scales. Field testing and psychometric validation were conducted in communities affected by Ebola disease in Uganda, mpox in the UK, and Nipah virus disease in Bangladesh. Content validity was established through cognitive interviews and expert Delphi scoring. 1008 respondents were included across the three countries. The final RAPID Community Stigma Scale (12 items) captures initial social stigma, provider or authority-related stigma, structural stigma, and enduring social stigma. The RAPID Self Stigma Scale (4 items) is unidimensional. Both scales were found to have robust psychometric properties, including content validity, structural validity (factor loadings ≥0·6), and reliability (ordinal alphas 0·79-0·92). High scores on both scales predicted an increased hesitancy to report symptoms and seek care. The RAPID Stigma Scales are validated tools for real-time assessment of stigma across outbreak settings, enabling responders to design targeted interventions to improve health outcomes and promote equitable care.
Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests EJ's research is funded in whole, or in part, by the Wellcome Trust (203132; 221719). The Trust and Confidence research programme at the Pandemic Sciences Institute at the University of Oxford is supported by an award from the Moh Foundation. CO has received lecture fees, honoraria, and travel scholarships from ViiV healthcare, Gilead Sciences, Medical Sciences Division, Janssen, and Bavarian Nordic. WN has received funding for mpox education and research activities from UK Health Security Agency, National Health Service England, the University of Edinburgh, and Queen Mary University, all paid to The Love Tank; travel funding from Preventx; and participated in the ViiV HIV PrEP Community Advisory Board (unpaid). DIR has received grants and travel funding from US Centers for Disease Control and Prevention (CDC). STo has received funding from The Federal Ministry of Education and Research, Germany, for a separate stigma-related research project. WRA has received grants from US CDC and support for travel from CEPI. KIAC and SMS have received institutional funding through an agreement with US CDC. AP is funded by a Rhodes Scholarship. All other authors declare no competing interests.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
